within Pharmacolibrary.Drugs.ATC.V;

model V04CD03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 20 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.0003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Sermorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It stimulates the secretion of growth hormone from the anterior pituitary, and was previously used diagnostically for evaluating growth hormone deficiency and therapeutically for certain pediatric growth disorders. Its use is currently discontinued or limited due to the availability of other therapeutics.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects based on peptide structure and published PK data for GHRH and similar analogues; no direct clinical PK data available for sermorelin.</p><h4>References</h4><ol><li><p>Esposito, P, et al., &amp; Veronese, FM (2003). PEGylation of growth hormone-releasing hormone (GRF) analogues. <i>Advanced drug delivery reviews</i> 55(10) 1279–1291. DOI:<a href=&quot;https://doi.org/10.1016/s0169-409x(03)00109-1&quot;>10.1016/s0169-409x(03)00109-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14499707/&quot;>https://pubmed.ncbi.nlm.nih.gov/14499707</a></p></li><li><p>Wilton, P, et al., &amp; Gunnarsson, R (1993). Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. <i>Acta paediatrica (Oslo, Norway : 1992). Supplement</i> 388 10–15. DOI:<a href=&quot;https://doi.org/10.1111/j.1651-2227.1993.tb12827.x&quot;>10.1111/j.1651-2227.1993.tb12827.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8329825/&quot;>https://pubmed.ncbi.nlm.nih.gov/8329825</a></p></li><li><p>Soule, S, et al., &amp; Millar, RP (1994). Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. <i>The Journal of clinical endocrinology and metabolism</i> 79(4) 1208–1211. DOI:<a href=&quot;https://doi.org/10.1210/jcem.79.4.7962295&quot;>10.1210/jcem.79.4.7962295</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7962295/&quot;>https://pubmed.ncbi.nlm.nih.gov/7962295</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V04CD03;
